

Press Release



ASKA Pharmaceutical Holdings Wins the “Best IR Award for Encouragement”

TOKYO, November 14, 2024 – ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Takashi Yamaguchi) is pleased to announce that the Company won the “Best IR Award for Encouragement” of the 2024 IR Award winners for the first time, presented by the Japan Investor Relations Association (Chairman: Isao Teshirogi, hereinafter “JIRA”).



The IR Award is designed to recognize companies which have been highly accredited in the investment community for their understanding and promotion of IR activities. This year marks the 29th year since the first IR Award. Of the JIRA member companies, 355 publicly-traded companies applied for the 2024 IR Award and a total of 12 companies were selected and received awards: the IR Grand Prix was given to two companies, the Best IR Awards to six, the IR Special Awards to two, and the Best IR Awards for Encouragement to two. The Company received the “Best IR Award for Encouragement” this year, following last year’s selection for the “Most Liked! IR Award”.

For more information, please visit the JIRA's website at <https://www.jira.or.jp/english/>.

ASKA Pharmaceutical Holdings was selected for Best IR Award for Encouragement in recognition of its achievements described as follows:

- The Company is active in disclosing information and makes efforts to enhance briefing sessions and materials.
- The presentation materials are well designed and easy to read.
- The Company provides detailed information for making earnings forecasts and serve as a useful starting point for investors to have deeper discussions.
- Its top management has a clear management vision and has shown a proactive attitude, such as by updating strategies in response to changing circumstances.
- The IR department is strengthening activities to present medium- to long-term growth strategies, host meetings with management for investors, and provide feedback to management from investors' perspectives.

The Company will strive to build a relationship of trust with its shareholders and investors and to further enhance dialogue with them, in order to sustainably increase its corporate value.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp